Skip to search formSkip to main contentSkip to account menu

Ariflo

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Cilomilast

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Selective Phosphodiesterase Inhibitors: A New Therapeutic Option in Inflammation and Autoimmunity.
2004
2004
Highly potent PDE4 inhibitors with therapeutic potential.
2004
2004
Orally active PDE4 inhibitor with therapeutic potential.
2002
2002
Pharmacological profile of a novel phosphodiesterase 4 inhibitor, 4-(8-benzo[1,2,5]oxadiazol-5-yl-[1,7]naphthyridin-6-yl)-benzoic acid (NVP-ABE171), a 1,7-naphthyridine derivative, with anti…
We investigated the pharmacology of a new class of phosphodiesterase 4 (PDE4) inhibitor, 6,8-disubstituted 1,7-naphthyridines, by… 
2002
2002
Cilomilast (Ariflo) does not potentiate the cardiovascular effects of inhaled salbutamol.
We investigated the safety and potential pharmacodynamic interactions arising from the co-administration of inhaled beta(2… 
2002
2002
Benefit of phosphodiesterase 4 inhibitors as supplemental therapy after lung transplantation concerning their antiproliferative effects: an experimental study using a heterotopic rodent model
Background. Recent advances in the understanding of immunomodulatory properties of phosphodiesterase 4 (PDE4) inhibitors… 
Review
2000
Review
2000
Chronic obstructive pulmonary disease: emerging therapies.
2000
2000
PDE inhibitors--Second William Harvey Research Conference. Drugs with an expanding range of therapeutic uses. 1-3 December 1999, Nice, France.
  • T. Torphy
  • IDrugs : the investigational drugs journal
  • 2000
  • Corpus ID: 30380859
This meeting underscored advances in the exploitation of cyclic nucleotide phosphodiesterases (PDEs) as drug targets. One… 
1999
1999
COPD: new developments and therapeutic opportunities.
1999
1999
Ariflo (SmithKline Beecham plc).
  • W. Brown
  • IDrugs : the investigational drugs journal
  • 1999
  • Corpus ID: 41061044
Ariflo (SB-207499) is a phosphodiesterase (PDE)4 inhibitor under development by SmithKline Beecham and in phase III and II… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)